

By: Senator(s) Younger

To: Drug Policy; Judiciary,
Division B

SENATE BILL NO. 2084

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,
2 TO ADD KRATOM TO THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AND
3 FOR RELATED PURPOSES.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

5 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is
6 amended as follows:

7 41-29-113.

8 **SCHEDULE I**

9 (a) Schedule I consists of the drugs and other substances,
10 by whatever official name, common or usual name, chemical name, or
11 brand name designated, that is listed in this section.

12 (b) **Opiates.** Unless specifically excepted or unless listed
13 in another schedule, any of the following opiates, including their
14 isomers, esters, ethers, salts and salts of isomers, esters and
15 ethers, whenever the existence of these isomers, esters, ethers
16 and salts is possible within the specific chemical designation:

17 (1) Acetyl-alpha-methylfentanyl;



- 18 (2) Acetyl Fentanyl
19 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;
20 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
21 cyclohexylmethyl]benzamide);
22 (4) Acetylmethadol;
23 (5) Allylprodine;
24 (6) Alphacetylmethadol, except levo-alphacetylmethadol
25 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);
26 (7) Alphameprodine;
27 (8) Alphamethadol;
28 (9) Alpha-methylfentanyl;
29 (10) Alpha-methylthiofentanyl;
30 (11) Benzethidine;
31 (12) Betacetylmethadol;
32 (13) Beta-hydroxyfentanyl;
33 (14) Beta-hydroxy-3-methylfentanyl;
34 (15) Betameprodine;
35 (16) Betamethadol;
36 (17) Betaprodine;
37 (18) Butyrl fentanyl
38 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
39 (19) Clonitazene;
40 (20) Dextromoramide;
41 (21) Diampromide;
42 (22) Diethylthiambutene;



- 43 (23) Difenoxin;
- 44 (24) Dimenoxadol;
- 45 (25) Dimepheptanol;
- 46 (26) Dimethylthiambutene;
- 47 (27) Dioxaphetyl butyrate;
- 48 (28) Dipipanone;
- 49 (29) Ethylmethylthiambutene;
- 50 (30) Etonitazene;
- 51 (31) Etoxeridine;
- 52 (32) Fentanyl-related substances, meaning any substance
- 53 not otherwise listed under another schedule and for which no
- 54 exemption or approval is in effect under Section 505 of the
- 55 Federal Food, Drug, and Cosmetic Act [21 USC 355] that is
- 56 structurally related to fentanyl by one or more of the following
- 57 modifications:
- 58 (A) Replacement of the phenyl portion of the
- 59 phenethyl group by any monocycle, whether or not further
- 60 substituted in or on the monocycle;
- 61 (B) Substitution in or on the phenethyl group with
- 62 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro
- 63 groups;
- 64 (C) Substitution in or on the piperidine ring with
- 65 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,
- 66 amino or nitro groups;



67 (D) Replacement of the aniline ring with any
68 aromatic monocycle whether or not further substituted in or on the
69 aromatic monocycle; and/or

70 (E) Replacement of the N-propionyl group by
71 another acyl group.

72 Fentanyl-related substances include, but are not limited to,
73 cyclopropyl fentanyl,

74 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

75 Furanyl-Fentanyl,

76 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

77 valeryl fentanyl,

78 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);

79 para-fluorobutyryl fentanyl,

80 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

81 para-methoxybutyryl fentanyl,

82 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

83 para-chloroisobutyryl fentanyl,

84 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

85 isobutyryl fentanyl,

86 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

87 cyclopentyl fentanyl,

88 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

89 and



90 ocfentanil,
91 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami
92 de);
93 (33) Furethidine;
94 (34) Hydroxypethidine;
95 (35) Ketobemidone (including the optical and geometric
96 isomers);
97 (36) Levomoramide;
98 (37) Levophenacylmorphane;
99 (38) 3-methylfentanyl;
100 (39) 3-methylthiofentanyl;
101 (40) Morpheridine;
102 (41) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
103 (42)
104 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpro
105 pionamide, its isomers, esters, ethers, salts and salts of
106 isomers, esters and ethers (other names:
107 beta-hydroxythiofentanyl);
108 (43) Noracymethadol;
109 (44) Norlevorphanol;
110 (45) Normethadone;
111 (46) Norpipanone;
112 (47) Para-fluorofentanyl;
113 (48) PEPAP
114 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);



- 115 (49) Phenadoxone;
- 116 (50) Phenampromide;
- 117 (51) Phenomorphan;
- 118 (52) Phenoperidine;
- 119 (53) Piritramide;
- 120 (54) Proheptazine;
- 121 (55) Properidine;
- 122 (56) Propiram;
- 123 (57) Racemoramide;
- 124 (58) Thiofentanyl;
- 125 (59) Tilidine;
- 126 (60) Trimeperidine;
- 127 (61) U-47700,

128 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

129 (c) **Opium derivatives.** Unless specifically excepted or
130 unless listed in another schedule, any of the following opium
131 derivatives, their salts, isomers and salts of isomers, whenever
132 the existence of these salts, isomers and salts of isomers is
133 possible within the specific chemical designation:

- 134 (1) Acetorphine;
- 135 (2) Acetyldihydrocodeine;
- 136 (3) Benzylmorphine;
- 137 (4) Codeine methylbromide;
- 138 (5) Codeine-N-Oxide;
- 139 (6) Cyprenorphine;



- 140 (7) Desomorphine;
141 (8) Dihydromorphine;
142 (9) Drotebanol;
143 (10) Etorphine (except hydrochloride salt);
144 (11) Heroin;
145 (12) Hydromorphinol;
146 (13) Methyldesorphine;
147 (14) Methyldihydromorphine;
148 (15) Monoacetylmorphine;
149 (16) Morphine methylbromide;
150 (17) Morphine methylsulfonate;
151 (18) Morphine-N-Oxide;
152 (19) Myrophine;
153 (20) Nicocodeine;
154 (21) Nicomorphine;
155 (22) Normorphine;
156 (23) Pholcodine;
157 (24) Thebacon.

158 (d) **Hallucinogenic substances.** Unless specifically excepted
159 or unless listed in another schedule, any material, compound,
160 mixture or preparation which contains any quantity of the
161 following substances, their salts, isomers (whether optical,
162 positional, or geometric) and salts of isomers, whenever the
163 existence of these salts, isomers and salts of isomers is possible
164 within the specific chemical designation:



- 165 (1) Alpha-ethyltryptamine;
- 166 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 167 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 168 (4) 2,5-dimethoxyamphetamine;
- 169 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 170 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
- 171 (2C-T-7);
- 172 (7) 4-methoxyamphetamine;
- 173 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 174 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 175 (10) 3,4-methylenedioxy amphetamine;
- 176 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 177 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
- 178 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl
- 179 MDA, MDE, MDEA);
- 180 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
- 181 known as N-hydroxy MDA, N-OHMDA, and
- 182 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 183 (14) 3,4,5-trimethoxy amphetamine;
- 184 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 185 (16) Alpha-methyltryptamine (also known as AMT);
- 186 (17) Bufotenine;
- 187 (18) Diethyltryptamine;
- 188 (19) Dimethyltryptamine;
- 189 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);



- 190 (21) Ibogaine;
- 191 (22) Lysergic acid diethylamide (LSD);
- 192 (23) (A) Marijuana (Cannabidiol contained in a legend
193 drug product approved by the Federal Food and Drug Administration
194 or obtained under Section 41-29-136 is exempt under Schedule I);
- 195 (B) Hashish;
- 196 (24) Mescaline;
- 197 (25) Parahexyl;
- 198 (26) Peyote;
- 199 (27) N-ethyl-3-piperidyl benzilate;
- 200 (28) N-methyl-3-piperidyl benzilate;
- 201 (29) Psilocybin;
- 202 (30) Psilocyn;
- 203 (31) Tetrahydrocannabinols, meaning
204 tetrahydrocannabinols contained in a plant of the genus Cannabis
205 (cannabis plant), as well as the synthetic equivalents of the
206 substances contained in the cannabis plant, or in the resinous
207 extractives of such plant, and/or synthetic substances,
208 derivatives, and their isomers with similar chemical structure and
209 pharmacological activity to those substances contained in the
210 plant such as the following:
- 211 (A) 1 cis or trans tetrahydrocannabinol;
- 212 (B) 6 cis or trans tetrahydrocannabinol;
- 213 (C) 3,4 cis or trans tetrahydrocannabinol.



214 (Since nomenclature of these substances is not
215 internationally standardized, compounds of these structures,
216 regardless of atomic positions, are covered.)

217 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

218 However, the following products are exempted from control:

219 (i) THC-containing industrial products made
220 from cannabis stalks (e.g., paper, rope and clothing);

221 (ii) Processed cannabis plant materials used
222 for industrial purposes, such as fiber retted from cannabis stalks
223 for use in manufacturing textiles or rope;

224 (iii) Animal feed mixtures that contain
225 sterilized cannabis seeds and other ingredients (not derived from
226 the cannabis plant) in a formula designed, marketed and
227 distributed for nonhuman consumption;

228 (iv) Personal care products that contain oil
229 from sterilized cannabis seeds, such as shampoos, soaps, and body
230 lotions (if the products do not cause THC to enter the human
231 body); and

232 (v) Processed cannabis plant extract, oil or
233 resin with a minimum ratio of twenty-to-one cannabidiol to
234 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and
235 diluted so as to contain at least fifty (50) milligrams of
236 cannabidiol per milliliter, with not more than two and one-half
237 (2.5) milligrams of tetrahydrocannabinol per milliliter;

238 (32) Phencyclidine;



239 (33) Ethylamine analog of phencyclidine (PCE);
240 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);
241 (35) Thiophene analog of phencyclidine;
242 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);
243 (37) 4-methylmethcathinone (mephedrone);
244 (38) 3,4-methylenedioxypropylvalerone (MDPV);
245 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);
246 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);
247 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
248 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
249 or 2,5-dimethoxy-4-iodophenethylamine;
250 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine
251 (2C-T-2);
252 (44)
253 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
254 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);
255 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
256 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine
257 (2C-P);
258 (48) 3,4-methylenedioxy-N-methylcathinone (methylone);
259 (49)
260 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
261 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);



262 (50)
263 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
264 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
265 (51)
266 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or
267 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
268 Cimbi-5);
269 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,
270 4-benzodiazepin-2-one (also known as Phenazepam);
271 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,
272 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene
273 (also known as Etizolam);
274 (54) Salvia divinorum;
275 (55) Synthetic cannabinoids. Unless specifically
276 excepted or unless listed in another schedule, any material,
277 compound, mixture, or preparation which contains any quantity of a
278 synthetic cannabinoid found in any of the following chemical
279 groups, whether or not substituted to any extent, or any of those
280 groups which contain any synthetic cannabinoid salts, isomers, or
281 salts of isomers, whenever the existence of such salts, isomers,
282 or salts of isomers is possible within the specific chemical
283 designation, including all synthetic cannabinoid chemical
284 analogues in such groups:
285 (A) (6aR,10aR)-9-(hydroxymethyl)-6,
286 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]



287 chromen-1-ol (also known as HU-210 or
288 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

289 (B) Naphthoylindoles and naphthylmethylindoles,
290 being any compound structurally derived from 3-(1-naphthoyl)indole
291 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted
292 in the indole ring to any extent, or in the naphthyl ring to any
293 extent;

294 (C) Naphthoylpyrroles, being any compound
295 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not
296 substituted in the pyrrole ring to any extent, or in the naphthyl
297 ring to any extent;

298 (D) Naphthylmethylindenenes, being any compound
299 structurally derived from 1-(1-naphthylmethyl)indene, whether or
300 not substituted in the indene ring to any extent or in the
301 naphthyl ring to any extent;

302 (E) Phenylacetylindoles, being any compound
303 structurally derived from 3-phenylacetylindole, whether or not
304 substituted in the indole ring to any extent or in the phenyl ring
305 to any extent;

306 (F) Cyclohexylphenols, being any compound
307 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether
308 or not substituted in the cyclohexyl ring to any extent or in the
309 phenolic ring to any extent;

310 (G) Benzoylindoles, whether or not substituted in
311 the indole ring to any extent or in the phenyl ring to any extent;



312 (H) Adamantoylindoles, whether or not substituted
313 in the indole ring to any extent or in the adamantoyl ring system
314 to any extent;

315 (I) Tetrahydro derivatives of cannabinal and
316 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,
317 except where contained in cannabis or cannabis resin;

318 (J) 3-Cyclopropylmethanone indole or
319 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by
320 substitution at the nitrogen atom of the indole ring, whether or
321 not further substituted in the indole ring to any extent, whether
322 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl
323 rings to any extent;

324 (K) Quinoliny ester indoles, being any compound
325 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny
326 ester, whether or not substituted in the indole ring to any extent
327 or the quinolone ring to any extent;

328 (L) 3-carboxamide-1H-indazoles, whether or not
329 substituted in the indazole ring to any extent and substituted to
330 any degree on the carboxamide nitrogen and
331 3-carboxamide-1H-indoles, whether or not substituted in the indole
332 ring to any extent and substituted to any degree on the
333 carboxamide nitrogen;

334 (M) Cycloalkanemethanone Indoles, whether or not
335 substituted at the nitrogen atom on the indole ring, whether or



336 not further substituted in the indole ring to any extent, whether
337 or not substituted on the cycloalkane ring to any extent.

338 (e) **Depressants.** Unless specifically excepted or unless
339 listed in another schedule, any material, compound, mixture, or
340 preparation which contains any quantity of the following
341 substances having a depressant effect on the central nervous
342 system, including their salts, isomers, and salts of isomers,
343 whenever the existence of such salts, isomers, and salts of
344 isomers is possible within the specific chemical designation:

- 345 (1) Gamma-hydroxybutyric acid (other names include:
346 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic
347 acid; sodium oxybate; sodium oxybutyrate);
348 (2) Mecloqualone;
349 (3) Methaqualone.

350 (f) **Stimulants.** Any material, compound, mixture or
351 preparation which contains any quantity of the following central
352 nervous system stimulants including optical salts, isomers and
353 salts of isomers unless specifically excepted or unless listed in
354 another schedule:

- 355 (1) Aminorex;
356 (2) N-benzylpiperazine (also known as BZP and
357 1-benzylpiperazine);
358 (3) Cathinone;
359 (4) Fenethylamine;
360 (5) Methcathinone;



361 (6) 4-methylaminorex (also known as
362 2-amino-4-methyl-5-phenyl-2-oxazoline);
363 (7) N-ethylamphetamine;
364 (8) Any material, compound, mixture or preparation
365 which contains any quantity of N,N-dimethylamphetamine. (Other
366 names include: N,N,-alpha-trimethyl-benzeneethanamine and
367 N,N-alpha-trimethylphenethylamine);

368 (9) **Synthetic cathinones.** (A) Unless listed in
369 another schedule, any compound other than bupropion that is
370 structurally derived from 2-Amino-1-phenyl-1-propanone by
371 modification in any of the following ways:

372 (i) By substitution in the phenyl ring to any
373 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide
374 substituents, whether or not further substituted in the phenyl
375 ring by one or more other univalent substituents;

376 (ii) By substitution at the 3-position with
377 an alkyl substituent;

378 (iii) By substitution at the nitrogen atom
379 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom
380 in a cyclic structure.

381 (B) The compounds covered in this paragraph (9)
382 include, but are not limited to, any material, compound, mixture
383 or preparation which contains any quantity of a synthetic
384 cathinone found in any of the following compounds, whether or not
385 substituted to any extent, or any of these compounds which contain



386 any synthetic cathinone, or salts, isomers, or salts of isomers,
387 whenever the existence of such salts, isomers or salts of isomers
388 is possible, unless specifically excepted or listed in another
389 schedule:

390 (i) 4-methyl-N-ethylcathinone ("4-MEC");

391 (ii) 4-methyl-alpha-pyrrolidinopropiophenone
392 ("4-MePPP");

393 (iii) Alpha-pyrrolidinopentiophenone
394 (" α -PVP");

395 (iv)

396 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");

397 (v) 2-(methylamino)-1-phenylpentan-1-one
398 ("pentedrone");

399 (vi)

400 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one

401 ("pentylone");

402 (vii) 4-fluoro-N-methylcathinone ("4-FMC");

403 (viii) 3-fluoro-N-methylcathinone ("3-FMC");

404 (ix)

405 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");

406 (x) Alpha-pyrrolidinobutiophenone (" α -PBP");

407 and

408 (xi)

409 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one

410 (N-ethylpentylone, ephylone).



411 (10) (i) Mitragynine; and

412 (ii) 7-hydroxymitragynine.

413 **SECTION 2.** This act shall take effect and be in force from
414 and after July 1, 2020.

